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1. Introduction 
The catecholamine-rich organelles of adrenal 
medulla, the chromaffin granules, are involved in trans- 
port, storage and secretion of these biogenic amines 
[l-4]. The isolated granules catalyse the uptake of 
large amounts of adrenaline and other biogenic amines 
by an ATP-dependent [5], uncoupler-sensitive [6] 
process. The granules have been found to contain a 
membrane-bound ATPase [7-lo]. The latter enzyme 
has been shown to translocate protons and to create 
an electrochemical proton gradient [ 1 l-161. More- 
over, indirect evidence has been obtained for the 
involvement of the pH gradient (ApH) component 
[ 141 as well as the membrane potential (A$) compo- 
nent of this gradient [ 171 in amine transport. The 
ability to drive amine transport by artificially imposed 
pH gradients (acidic inside) provides direct evidence 
for the participation of at least ApH as an immediate 
driving force for the process [ 18,191. 
The ability of the granules [5] and isolated granule 
membrane vesicles [20] to accumulate various 
biogenic amines, as well as the mutual inhibition on 
transport of the amines [5] suggests the presence of a 
single carrier with a rather broad specificity. This may 
also serve to explain the inhibitory action of reserpine 
which also has been reported to act as a competitive 
inhibitor of the transport process [21]. In apparent 
contrast to this observation is the reported irrevers- 
ibility of this drug (cf. [22]). 
Using isolated membranes lacking endogenous 
amines, we provide here additional evidence for a single 
ElsevierlNorth-Holland Biomedical Press 
translocator for biogenic amines in the chromaffin 
granule membrane. Moreover, we show that reserpine 
indeed acts as a competitive inhibitor and that its 
suggested irreversibility is only apparent, due to the 
hydrophobicity of the drug. 
2. Materials and methods 
2.1. Chemicals 
D,L-[7-3H]adrenaline hydrochloride 
(10.3 Ci/mmol), D,L-[7-3H]noradrenaline hydro- 
chloride (11 Ci/mmol) and 5-hydroxy [G3H] trypt- 
amine (0.5 Ci/mmol) were purchased from Amersham, 
aselectin was from Associated Concentrates, Woodside 
NY. Unlabelled biogenic amines and all other chemicals 
were from commercial sources and of the highest 
purity available. 
2.2. Chromaffin granule membrane vesicles 
These were isolated as in [ 191. 
2.3. Transport assays 
ATP-dependent transport and ApH-dependent 
transport were assayed as in [ 191. When biogenic 
amines other than adrenaline were assayed, their final 
concentrations were (I 1 Ci/mmol) 0.22 PM 
D,L[7-3H]noradrenaline and 5 PM (0.5 Ci/mmol) 
5-hydroxy [G-3H] tryptamine (serotonin). 
2.4. Protein determinations 
These were as in [23]. 
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3. Results and discussion 
The rate of ATP-dependent adrenaline transport 
in chromaffin granule membrane vesicles is dependent 
on the external solute concentration and is a saturable 
function. When the data are plotted according to 
Lineweaver-Burk, the app. V,,,,, for noradrenaline 
and serotonin uptake are 4.9 and 1.8 ,umol/min.mg 
protein, respectively and the respective app. Km 
values are 12.5 PM and 4.3 PM (table 1). The app. Km 
values are in good agreement with the affinity con- 
stants determined [20]. Transport of adrenaline, nor- 
adrenaline and serotonin is competitively inhibited 
by each of the other amines as well as by dopamine 
and reserpine (table 1). In the case of adrenaline, nor- 
adrenaline and serotonin the app. Km of each trans- 
port substrate correlates very well with its apparent 
inhibition constant on the transport of the other two 
amines. These data support the notion that a single 
carrier is responsible for the transport of the different 
amines in this preparation. 
The ATP-dependent amine transport is very likely 
the result of two sequential processes: 
(i) Generation of a proton electrochemical gradient 
by the membrane-bound ATPase; 
(ii) Utilisation of (at least) the ApH component to 
drive the carrier-mediated accumulation. There- 
fore, uptake driven by an artificially imposed 
Table 2 
Effect of reserpine and catecholamines on pHdriven 
adrenaline transport 
Additions Adrenaline uptake 
(pmol/mg protein) 
None 14.2 
L-Noradrenaline, 50 PM 4.5 
Dopamine, 50 PM 3.2 
Reserpine, 1 bM 0.8 
ApII-driven transport was measured as in section 2. The reac- 
tion was initiated by addition of 10 ~1 membrane vesicle suspen- 
sion (45 ~g protein) and terminated after 1 min. Inhibitors 
were added 30 s prior to the membranes 
ApH should also be inhibited by other biogenic 
amines. 
As shown in table 2, adrenaline accumulation 
induced by ApH is, like ATP-dependent transport, 
inhibited by reserpine, dopamine and noradrenaline 
(table 2). Therefore, it is concluded that the ApH-driven 
process is carrier mediated as well. 
Reserpine has been reported to inhibit catechol- 
amine uptake into subcellular storage vesicles in various 
preparations such as those from brain tissue and the 
adrenal medulla [5,22]. Reserpine was shown to behave 
[21] as a competitive inhibitor of adrenaline trans- 
port in the adrenal medullary vesicles. However, other 
Table 1 
Apparent Km and Ki values of biogenic amine transport 
Inhibitor -4pparent inhibition constants (PM) of the transport of: 
Adrenaline Noradrenaline Serotonin 
L-Adrenaline (18.5) 19.4 20.1 
L-Noradrenaline 14.1 (12.5) 13.3 
Serotonin 2.8 2.9 (4.3) 
Dopamine 8.7 6.2 6.8 
Reserpine 0.016 n.d. 0.019 
ATE-dependent transport was measured as in section 2. The reaction was initiated 
by addition of 10 ~1 membrane vesicle suspension (30-50 IJ~ protein) and 
terminated after 3 min. The data were plotted according to Lineweaver-Burk and 
the appropriate constants were calculated. The data in parenthesis are the app Km 
values. Since in the case of adrenaline and noradrenaline D,L mixtures were used, 
the app. Km values should be corrected according to [ 271. This is not likely to 
change the good agreement bctwcen the Km and Ki values. For instance, the Km 
for noradrenaline corrected [ 271 using the affinity constants for the D and L 
isomer yields a value of 15.6 PM 
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TIME (min) 
Fig. 1. Reversibility of the reserpine inhibition on adrenaline 
transport. Chromaffin granule membrane vesicles (0.5 mg 
protein/ml) were incubated at 37°C in a medium containing 
0.3 M sucrose, 10 mM K-Hepes (pH 8.5), 2.5 mM MgSO, and 
5 mM KC1 in the presence or absence of 0.6 PM reserpine. 
After 5 min incubation, aliquots were taken to assay ATP- 
dependent adrenaline accumulation, and remaining mem- 
branes were diluted IO-fold in a medium of the same com- 
position without reserpine but containing liposomes 
(1.3 pmol lipid/ml) and further incubated at 37°C. After 
5 min, the suspension was centrifuged at 40 000 X g for 
20 min. The pellet was resuspended in the above liposome- 
.containing medium and the above-described incubation and 
centrifugation procedure was repeated twice. Finally, the 
pellet was resuspended and assayed as described. In parallel 
experiments the phospholipids were omitted from the incuba- 
tion and washing medium. Liposomes were prepared from 
asolectin using a bath-type sonifier. (A) Unwashed mem- 
brane vesicles: Control (o- - -o), + 0.6 PM reserpine (o- - -0). 
(B) Membrane vesicles treated with reserpine (o- - -0, a- --a) 
and washed in the presence (o- - -0) or in the absence 
(a- - a) of liposomes. Washed vesicles not treated with 
reserpine (*- - -0). 
observations suggested that the inhibition is irrevers- 
ible (reviewed in [22]). Our kinetic data on the 
isolated chromaffm granule membranes support the 
contention that reserpine competitively inhibits the 
transport system. The app. Ki (16 nM) is in good 
agreement with the Ki value obtained with the intact 
granules [21]. The action of reserpine in the isolated 
membranes also seemed to be irreversible (fig.1). Thus, 
pretreatment of the membranes with 1 PM reserpine 
completely inhibits adrenaline transport, even after 
three consecutive washings. A possible explanation 
for the apparent irreversibility of the action of this 
compound might be its highly hydrophobic nature. 
Indeed, when phospholipid vesicles are included in 
the washing medium, an almost complete reversal of 
the inhibition by reserpine is observed (fig.lB). It 
should be pointed out that the transport activity after 
reversal is still reserpine sensitive (data not shown). 
According to our hypothesis, the phospholipid vesicles 
provide an hydrophobic milieu which is able to remove 
the inhibitor from the chromaffin granule membranes. 
The mechanism of accumulation described for the 
chromaffm granule may well apply to other subcellular 
organelles that store biogenic amines. For instance, in 
certain neuronal preparations [24] and platelets [25], 
reserpine induces the release of catecholamines and 
.5-hydroxytryptamine, respectively, but does not 
inhibit uptake through the plasma membrane [26]. 
These effects of reserpine may reflect the presence of 
two types of transport systems for biogenic amines: 
(i) An Na+-dependent carrier for translocation across 
the plasma membrane that is insensitive to 
reserpine; 
(ii) An H’coupled system for accumulation across the 
storage organelle membrane that is inhibited by 
reserpine. 
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